Public awareness of kratom remains low. Investigators from the Annenberg Public Policy Center reported that roughly two-thirds of Americans had never heard of the plant. Among those familiar with it, many cannot reliably distinguish the traditional powdered leaf from newer semi-synthetic products that concentrate specific alkaloids. Clinicians should recognize that the market now includes whole-leaf powders, extracts, tinctures, tablets, gummies, and drink powders — products that vary widely in potency and composition.
Kratom leaves contain dozens of alkaloids; mitragynine is the most abundant and the best understood. The study team noted mitragynine acts as a partial agonist at mu-opioid receptors, producing less receptor activation than full agonists such as fentanyl or oxycodone. Dosing practices are heterogeneous in real-world use. The source did not report evidence-based dosing recommendations and emphasized large variation in both product potency and personal regimens.
Anecdotal accounts collected by STAT paint a mixed picture. Some users describe kratom as a mild stimulant at low doses with coffee-like effects. Others report analgesia at higher doses and use it to manage chronic pain or to mitigate opioid withdrawal symptoms. One user reported taking about 70–75 mg of mitragynine every six hours and described functional improvement without euphoria. Another user described severe addiction after sampling a semi-synthetic tablet; he later formed a recovery group that offers virtual meetings. The study team observed that withdrawal from natural kratom has appeared mild on opioid withdrawal scales in some studies, with anxiety, fatigue, GI symptoms, and restlessness described.
Research cited by the authors indicated that some studies have found up to around 38% of kratom users may develop use disorders. The source, however, emphasized that much of the literature on dependence and withdrawal is limited, consisting of case reports, series, and observational studies rather than randomized controlled trials.
Investigators and clinicians highlighted three compounds of clinical concern. Mitragynine is the primary alkaloid in the leaf. 7-hydroxymitragynine (7-OH) does not appear in fresh leaf but exists in dried leaf powder in small quantities and forms as a metabolite when mitragynine is processed by the body. Like mitragynine, 7-OH is a partial mu-opioid receptor agonist, but users and clinicians report stronger sedative effects with concentrated 7-OH products.
Mitragynine pseudoindoxyl (MGPI) is another metabolite that has drawn regulatory attention. The DEA initially proposed banning MGPI at any quantity; later proposals have aimed to limit both MGPI and 7-OH based on the ratio of those compounds to mitragynine in a product. The source noted that the change in DEA posture arose because trace amounts of MGPI might appear naturally in kratom, but safety of trace amounts remains unclear.
Semi-synthetic products containing 7-OH and MGPI are sold in doses that have increased over time. Early tablets commonly contained roughly 12–14 mg of 7-OH; current market offerings can include tablets labeled at 25, 50, or even 100 mg, along with gummies and concentrated liquid shots. The authors reported that these changes have raised alarm among clinicians and public health officials about addiction potential and more severe withdrawal compared with natural kratom.
National surveillance shows rising harms associated with kratom. Data from the National Poison Data Center documented a 1,200% increase in kratom-related exposure reports from 2015 (258 reports) to 2025 (3,434 reports). The poison center records included 233 deaths over that decade, most of which involved other substances such as opioids, benzodiazepines, stimulants, or alcohol.
State-level reporting added further signals. A 2023 investigative report cited in the source estimated more than 580 overdose deaths involving kratom products in Florida over nearly a ten-year span. The authors cautioned that attribution is complex: because 7-OH and MGPI are metabolites of mitragynine, isolating a single causal agent in toxicology can be difficult. The source emphasized that many commercial products test out of alignment with their labels; investigators reported measurable concentration discrepancies and, in some cases, unlabeled compounds detected in products.
Regulatory agencies and local jurisdictions are responding. The source documented that federal policy actions were pending, with the DEA circulating proposals to limit or ban certain metabolites. Multiple states and smaller localities have issued emergency bans on 7-OH, and some have moved to restrict all kratom products. The source described industry lobbying and litigation that have influenced federal rulemaking: an updated DEA proposal, influenced by a lobbyist, would allow small amounts of MGPI in products if ratios to mitragynine meet proposed limits.
Wrongful-death lawsuits and recent test results have been presented publicly, drawing attention to possible contamination or adulteration of products. The source reported case-based concerns rather than definitive causal proof linking specific formulations to overdoses.
The authors noted clear research gaps. High-quality, controlled data on clinical efficacy for pain or opioid withdrawal are lacking, and no standardized dosing guidance exists. The safety profile of low-level MGPI or 7-OH exposure in natural kratom remains unclear. Investigators are conducting studies — for example, a Yale-led study on 7-OH tolerance and withdrawal was cited as underway — but much of the current evidence is case-report–based.
Practical unanswered questions documented in the source include: how often concentrated 7-OH or MGPI causes severe withdrawal compared with natural kratom; whether trace metabolite levels in natural powder pose clinically meaningful risks; and how best to regulate mixtures that contain variable ratios of mitragynine and its metabolites. Next regulatory milestones noted were ongoing DEA rulemaking and active state emergency bans. Those regulatory processes, and the limited and heterogeneous surveillance data, were the final concrete items the source left open for further study.